Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 in Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
NCT05983432Phase 1Recruiting
- Sponsor
- SystImmune Inc.
- Start
- Aug 2023
- Primary completion
- Apr 2030
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
Phase 1, open-label trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), esophageal cancer, small cell lung cancer (SCLC) and 7 more (2 arms), sponsored by SystImmune Inc. Primary endpoints: Dose-limiting toxicities at 1 year, Serious Adverse Events and treatment-emergent adverse events at 1 year and 5 more. Started Aug 2023; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)esophageal cancersmall cell lung cancer (SCLC)nasopharyngeal carcinoma (NPC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05983432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983432.